OncoTalks | Oncology Insights at Your Fingertips

Case Journey: How ADCs are Transforming HER2-Low Metastatic Breast Cancer Treatment

Introducing a new and exciting video podcast experience: OncoTalks Case Journey. Tune into our debut episode as Dr. Paul Conkling and Dr. Mabel Mardones discuss two compelling cases of metastatic ER-positive breast cancer, emphasizing the role of antibody drug conjugates (ADCs) in treatment. They explore the challenges of HER2-low classification and the importance of early access to innovative therapies for improving patient outcomes. The conversation highlights the need for precise diagnostic approaches and the evolving landscape of breast cancer. 

Advancing mCRC Care: Innovations and Insights in Modern Cancer Treatment

In this episode of OncoTalks, Dr. Paul Conkling and Dr. David Cosgrove explore the latest advancements in mCRC treatment, highlighting the shift from traditional chemotherapy to innovative targeted therapies driven by genomic insights. We discuss the role of next-generation sequencing, new therapeutic agents, and clinical trials, while emphasizing personalized care, addressing treatment challenges, side effects, and financial considerations, offering a hopeful outlook on improved survival rates and future therapies with reduced toxicity.

HER2-low Uncovered: A Phase 1 Retrospective Study on Testing & Concordant Treatment

Join us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategies to enhance patient outcomes.

Unlocking the Future of Breast Cancer Treatment and the Critical Role of HER2 Testing

Join us as we explore the transformative potential of HER2 testing in breast cancer care. In this episode of OncoTalks, Dr. Paul Conkling and Dr. Erika Hamilton share cutting-edge insights that every oncologist should know to stay at the forefront of breast cancer treatment. Tune in to discover how HER2 testing is reshaping the landscape of personalized cancer therapy.

Genomic Testing in the Clinic

Join Dr. Robert Reid and Dr. Sreeni Chittoor as they explore the revolutionary impact of genomic testing in redefining cancer treatment. We focus on advanced solid tumors, such as non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, examining how these state-of-the-art technologies are leading to more personalized and effective treatment strategies.

Exploring CAR-T Cell Therapy

Join Dr. Paul Conkling and Dr. Akash Mukherjee as they explore CAR-T Therapy from design of treatment through the patient journey.

Bispecific Antibody Therapies in the Community for DLBCL and FL

Join Dr. Ira Zackon and Dr. David Andorsky on today’s episode of OncoTalks, as they discuss the expanding role of bispecific antibody therapies in the community for Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL).

NSCLC METex14 Skipping

In this episode of OncoTalks, Dr. David Waterhouse and Dr. Paul Conkling discuss NSCLC and the groundbreaking developments in treating patients with MET exon 14 (METex14) skipping mutations. We review the science behind these targeted therapies, their clinical applications, and the impact on patient outcomes.

Exploring Second Line Treatments for Extensive Stage Small Cell Lung Cancer

In this episode, Dr. David Waterhouse and Dr. Paul Conkling discuss the evolving landscape of second line treatments for extensive stage small cell lung cancer (SCLC). They review the latest research, promising therapies, and the impact of these treatments on patient quality of life. This episode offers vital information to help navigate treatment options and empower patients. Don’t miss this engaging discussion on a crucial topic in oncology, filled with expert insights!

Managing Ocular Side Effects in ELAHERE Treatment

In this episode, Dr. Kristen Lamoreau, OD, delves into the critical role eye care professionals play in managing ocular adverse events for patients undergoing treatment with ELAHERE, the first and only antibody-drug conjugate targeting folate receptor alpha (FRα). As a groundbreaking treatment for certain types of resistant ovarian cancer, ELAHERE is associated with ocular toxicities, necessitating a collaborative approach between eye care providers and oncology teams.